

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2877)

TURNOVER FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2022

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company”) is pleased to announce that, the turnover of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2022 based on its management accounts which have not been reviewed by the auditors, was RMB 2,848 million, representing an increase of 21.9% as compared with the same period of 2021, and in particular:

- Turnover of injection products increased by 11.5% to RMB 1,084 million;
- Turnover of soft capsule products increased by 11.9% to RMB 431 million;
- Turnover of granule products increased by 14.8% to RMB 408 million;
- Turnover of TCM formula granule products increased by 56.0% to RMB 782 million; and
- Turnover of products in other forms increased by 14.4% to RMB 143 million.

In terms of product mix, injection products, soft capsule products, granule products and TCM formula granule products accounted for approximately 38.1%, 15.1%, 14.3% and 27.4% of the total turnover respectively for the nine months ended 30 September 2022.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 11 November 2022

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Liu Tiejun; the non-executive director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Mr. Liu Shun Fai and Mr. Yew Yat On.